BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient
tool to cure standard-risk acute lymphocytic leukemia (ALL) in first CR (CR1) but the choice
between BU-based or TBI-based conditioning regimens still remains controversial. In this
study, the safety and efficacy of BUCY and TBICY myeloablative conditioning regimens in
patients undergoing allo-HSCT for ALL in CR1 are evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Guangzhou First People's Hospital Peking University People's Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Sun Yat-sen University Third Affiliated Hospital, Sun Yat-Sen University Zhujiang Hospital